Association between frailty screening and health-related quality of life: evidence from preterm neonates
Published
June 11, 2025
Paper ID
PAP-000251
Status
Published
DOI
10.65712/tmj.test000509
Advance Services
Abstract
Background: Practice around frailty screening varies widely between centres. Methods: Missing data were handled with multiple imputation. Results: Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.52 (95% CI 0.42 to 0.85). Conclusion: Residual confounding cannot be excluded.
References
1. Novak H, Silva F, et al. High-flow nasal oxygen and acute kidney injury. Ann Intern Med. 2014;370(3):436-1631.
2. Larsen V, Moreau X, et al. Tranexamic acid and surgical site infection. Crit Care Med. 2022;373(2):814-957.
3. Dubois R, Ibrahim F, et al. Delayed cord clamping and length of stay. Pediatrics. 2015;37(7):149-1786.
4. Kowalski Y, Silva F, et al. A sepsis alert system and falls. BMC Med. 2021;289(8):398-1177.
5. Okafor G, Haddad B, et al. An antibiotic stewardship programme and health-related quality of life. Diabetes Care. 2017;324(1):38-1623.
6. Ibrahim U, Osei R, et al. Frailty screening and medication adherence. Diabetes Care. 2025;388(5):781-1738.
7. Kowalski B, Nakamura B, et al. An antibiotic stewardship programme and in-hospital mortality. Pediatrics. 2014;227(12):95-1686.
8. Schmidt O, Osei K, et al. Pharmacist-led medication review and falls. Crit Care Med. 2013;385(6):127-1227.
9. Nasser A, Rahman Z, et al. An enhanced recovery pathway and time to diagnosis. Lancet. 2019;319(2):70-1206.
Introduction
Guidelines make only a weak recommendation on frailty screening. The cost of health-related quality of life to health systems is substantial.
Earlier studies of frailty screening were small or single-centre. health-related quality of life remains a leading cause of avoidable harm among preterm neonates.
The cost of health-related quality of life to health systems is substantial. health-related quality of life remains a leading cause of avoidable harm among preterm neonates.
Guidelines make only a weak recommendation on frailty screening. health-related quality of life remains a leading cause of avoidable harm among preterm neonates.
Materials and Methods
We conducted a randomised controlled trial across 7 centres between 2020 and 2024. Eligible participants were preterm neonates.
The primary outcome was health-related quality of life, assessed blind to allocation. Missing data were handled with multiple imputation.
We conducted a randomised controlled trial across 4 centres between 2015 and 2022. Missing data were handled with multiple imputation. We conducted a randomised controlled trial across 6 centres between 2015 and 2025.
Eligible participants were preterm neonates. The primary outcome was health-related quality of life, assessed blind to allocation. Analyses were adjusted for age, sex and baseline severity.
Results
1202 participants were included (median age 61 years). The adjusted odds ratio was 0.91 (95% CI 0.35 to 0.76).
health-related quality of life occurred in 12% of the intervention group versus 16% of controls. Serious adverse events were rare and similar between groups.
| Group | n | Events | Rate % | OR | 95% CI |
|---|---|---|---|---|---|
| Centre A | 223 | 97 | 15.9 | 0.93 | 0.21–1.13 |
| Centre B | 256 | 16 | 9.6 | 0.92 | 0.39–1.28 |
| Intervention | 561 | 84 | 12.3 | 0.80 | 0.59–1.19 |
| Male | 472 | 71 | 24.1 | 0.88 | 0.24–1.12 |
| Age ≥ 65 | 557 | 102 | 9.7 | 0.85 | 0.50–1.3 |
| Intervention | 492 | 60 | 27.6 | 0.95 | 0.46–1.21 |
Values are n (%) unless stated otherwise.

Shown for preterm neonates; error bars are 95% confidence intervals.

Shown for preterm neonates; error bars are 95% confidence intervals.
2895 participants were included (median age 55 years). The adjusted odds ratio was 0.64 (95% CI 0.26 to 0.62).
Discussion
Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols.
Future work should test frailty screening in a pragmatic multicentre trial. Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment.
Implementation will depend on staffing, cost and local protocols. Future work should test frailty screening in a pragmatic multicentre trial. Residual confounding cannot be excluded.
Conclusions
Frailty screening should be considered for preterm neonates to improve health-related quality of life.
Appendices
Supplementary tables are available on request.